Key result
Novel LMNA R133L mutation links to generalized lipoatrophy, severe metabolic disease, and hypertrophic cardiomyopathy.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Case report reveals a novel LMNA mutation causing lipoatrophy, severe metabolic defects, and cardiomyopathy in an adult, indicating an expanded clinical spectrum for laminopathies.
A-Type lamins, arising from the LMNA gene, are intermediate filaments proteins that belong to the lamina, a ubiquitous nuclear network. Naturally occurring mutations in these proteins have been shown to be responsible for several distinct diseases that display skeletal and/or cardiac muscle or peripheral nerve involvement. These include familial partial lipodystrophy of the Dunnigan type and the mandibuloacral dysplasia syndrome. The pathophysiology of this group of diseases, often referred to as laminopathies, remains elusive. We report a new condition in a 30-yr-old man exhibiting a previously undescribed heterozygous R133L LMNA mutation. His phenotype associated generalized acquired lipoatrophy with insulin-resistant diabetes, hypertriglyceridemia, hepatic steatosis, hypertrophic cardiomyopathy with valvular involvement, and disseminated whitish papules. Immunofluorescence microscopic analysis of the patient's cultured skin fibroblasts revealed nuclear disorganization and abnormal distribution of A-type lamins, similar to that observed in patients harboring other LMNA mutations. This observation broadens the clinical spectrum of laminopathies, pointing out the clinical variability of lipodystrophy and the unreported possibility of hypertrophic cardiomyopathy and skin involvement. It emphasizes the fact that the diagnosis of genetic alterations in A-type lamins requires careful and complete clinical and morphological investigations in patients regardless of the presenting signs.
No takes yet. Share an insight, caveat, or question.
Caux et al. (2003) conducted a case report in Laminopathy associated with R133L LMNA mutation (generalized lipoatrophy, insulin-resistant diabetes, hepatic steatosis, hypertrophic cardiomyopathy, and leukomelanodermic papules) (n=1). Heterozygous R133L LMNA mutation was evaluated on Clinical phenotype and cellular nuclear morphology in cultured skin fibroblasts. A novel heterozygous R133L LMNA mutation in a 30-year-old man was associated with generalized lipoatrophy, insulin-resistant diabetes, hepatic steatosis, and hypertrophic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: